J&J nasal spray gets U.S. approval as first new type of anti-depressant in decades

(Reuters) – The U.S. Food and Drug Administration on Tuesday said it approved a Johnson & Johnson nasal spray antidepressant for people resistant to other treatments but placed restrictions on use of the drug, which it warned could be misused and abused.

FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake/File Photo

The approval of nasal spray esketamine marks the first new type of treatment for depression in more than 30 years and has raised hopes for its relatively fast action and ability to treat some otherwise unreachable patients.

Esketamine would be sold under the brand name Spravato and is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”. To prevent abuse, patients must take the drug in a doctor’s office or medical facility and cannot take it home.

Currently available anti-depressants such as Eli Lilly and Co’s Prozac work on neurotransmitters like serotonin and norepinephrine, but most drugs take at least four weeks to show effect and fail to produce an adequate response in about 30 percent to 40 percent of patients with major depressive disorder (MDD).

“Spravato has the potential to change the treatment paradigm and offer new hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies,” said Mathai Mammen, global head of J&J’s Janssen Research & Development.

Spravato has been touted as an asset with blockbuster potential and is expected to improve investor sentiment toward the growth prospects of J&J’s pharma unit Janssen, as its top-selling rheumatoid arthritis drug Remicade faces increased competition from cheaper biosimilars.

The treatment carries a boxed warning – FDA’s harshest – flagging the risk for sedation and difficulty with attention, judgment and thinking, abuse and misuse, and suicidal thoughts after administration of the drug.

Spravato is absorbed by the lining of the nasal passages and into the blood stream and will be used along with a newly prescribed oral antidepressant, Johnson & Johnson said in a statement here

During clinical trials, Spravato was found to relieve depression symptoms within 24 hours in some patients, said Janssen spokesman Greg Panico.

The approval comes after an FDA advisory panel in February voted heavily in favor of the drug esketamine, saying its benefits outweighed the risks.

However, the panel members echoed concerns raised by FDA staffers regarding the increased risk of sedation, dissociation and higher blood pressure observed in the study.

The drug is also being tested in patients with depression who are at a high risk of committing suicide.

Recent research shows that depression involves deterioration of the quality and number of nerve cell connections in areas of the brain related to mood. J&J’s drug helps restore these nerve cell connections in the brain, leading to an improvement in depression symptoms, according to the company. Over 300 million people globally live with major depressive disorders, and the incidence of attempted suicide in people with this condition is about 20-fold higher than that among those without the disorder.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Cynthia Osterman and Lisa Shumaker

Source

more recommended stories

  • Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 million

    (Reuters) – Bayer AG and Johnson.

  • Texas petrochemical fire prompts hundreds to visit health clinic

    DEER PARK, Texas (Reuters) – Hundreds.

  • U.S. Customs details China pork seizure; importers could pay fine

    CHICAGO (Reuters) – U.S. border agents.

  • FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

    (Reuters) – The U.S. Food and.

  • Tyson recalls tons of chicken strips for possible metal contamination

    (Reuters) – Tyson Foods Inc is.

  • Mississippi governor signs ‘heartbeat’ abortion ban

    (Reuters) – Mississippi’s Republican governor signed.

  • Congo Ebola outbreak spreads to city of Bunia

    GOMA, Democratic Republic of Congo (Reuters).

  • Second U.S. jury finds Bayer’s Roundup caused cancer

    (Reuters) – A U.S. jury on.

  • Soda, sports drinks tied to higher risk of early death

    (Reuters Health) – People who consume.

  • Apple Watch detects irregular heart beat in large U.S. study

    (Reuters) – The Apple Watch was.

  • Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

    (Reuters) – Non-invasive heart valve replacement.

  • U.S. seizes 1 million pounds of pork from China on swine fever concerns

    WASHINGTON (Reuters) – U.S. border agents.

  • Teen drivers reaching for objects more likely to crash

    (Reuters Health) – Teen drivers who.

  • Quality of surgical care across a hospital network may vary

    (Reuters Health) – Just because the.

  • California jury awards $29 million to woman with cancer who used J&J talc

    (Reuters) – A California jury on.

  • As wildfires devour communities, toxic threats emerge

    PARADISE, Calif. (Reuters) – As an.

  • Court allows Ohio law blocking Planned Parenthood funding

    FILE PHOTO: A sign is pictured.

  • FDA approves Pfizer’s biosimilar to Roche’s Herceptin

    FILE PHOTO: The logo of U.S..

  • Mumps, other outbreaks force U.S. detention centres to quarantine over 2,000 migrants

    (Reuters) – Christian Mejia thought he.

  • Measles outbreak in New Zealand’s Canterbury widens to 20

    MELBOURNE (Reuters) – Thousands of vaccines.

  • OxyContin maker Purdue Pharma loses bid to delay opioid epidemic trial

    (Reuters) – OxyContin maker Purdue Pharma.

  • Roche’s Tecentriq wins U.S. approval for aggressive breast cancer

    FILE PHOTO: The logo of Swiss.

  • Knee surgery for torn cartilage may not be worthwhile

    (Reuters Health) – Many middle-aged and.

  • FDA finds asbestos in three Claire’s cosmetics products

    (Reuters) – The U.S. Food and.

  • London HIV patient becomes world’s second AIDS cure hope

    LONDON, March 4 (Reuters) – An.

  • Eli Lilly seeks to quell drug price anger with cheaper insulin

    (Reuters) – Drugmaker Eli Lilly announced.

  • Ebola treatment centre in Congo reopens after attack – ministry

    KINSHASA (Reuters) – An Ebola treatment.

  • Quebec appeals court upholds C$15 billion tobacco class action ruling

    MONTREAL/LONDON (Reuters) – The Court of.

  • Gastric bypass surgery tied to diabetes remission

    (Reuters Health) – Three in four.

  • After attacks, MSF suspends Ebola treatment in epicenter of Congo outbreak

    DAKAR (Reuters) – Medecins Sans Frontieres.

  • Yoga linked to lowered blood pressure with regular practice

    (Reuters Health) – Adults who practice.

  • Congo Ebola center set on fire after armed attack

    GOMA, Democratic Republic of Congo (Reuters).